Vanguard Group Inc. Sells 172,147 Shares of Alkermes plc $ALKS

Key Points

• Vanguard trimmed its stake in Alkermes by 0.9%, selling 172,147 shares and now holds 18,007,364 shares (about 10.91%) valued at roughly $503.8 million.
• Q1 results beat expectations, with revenue up about 28% year‑over‑year and management citing LUMRYZ momentum as a key driver of commercial growth.
• Despite the beat, Alkermes narrowed FY‑2026 guidance—EPS roughly ($0.521)–($0.405) and revenue ~$1.7–1.8B, well below street EPS expectations—though analysts retain a consensus "Moderate Buy" and a ~$44.71 price target.

Vanguard Group Inc. cut its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,007,364 shares of the company's stock after selling 172,147 shares during the period. Vanguard Group Inc. owned about 10.91% of Alkermes worth $503,846,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. American Century Companies Inc. grew its stake in shares of Alkermes by 20.2% during the 3rd quarter. American Century Companies Inc. now owns 4,397,471 shares of the company's stock valued at $131,924,000 after acquiring an additional 740,248 shares during the period. Victory Capital Management Inc. raised its stake in Alkermes by 43.1% during the 3rd quarter. Victory Capital Management Inc. now owns 344,202 shares of the company's stock worth $10,326,000 after acquiring an additional 103,749 shares during the period. Public Sector Pension Investment Board raised its stake in Alkermes by 11.6% during the 3rd quarter. Public Sector Pension Investment Board now owns 710,700 shares of the company's stock worth $21,321,000 after acquiring an additional 73,787 shares during the period. Tudor Investment Corp ET AL purchased a new position in Alkermes during the third quarter valued at approximately $1,691,000. Finally, Artisan Partners Limited Partnership lifted its holdings in Alkermes by 36.8% during the third quarter. Artisan Partners Limited Partnership now owns 2,109,772 shares of the company's stock valued at $63,293,000 after purchasing an additional 567,965 shares in the last quarter. Institutional investors own 95.21% of the company's stock.

Alkermes Price Performance

Alkermes stock opened at $36.25 on Wednesday. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.56. The firm's 50 day moving average price is $31.53 and its 200-day moving average price is $30.98. The stock has a market cap of $6.03 billion, a P/E ratio of 25.35 and a beta of 0.31.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported $0.29 earnings per share for the quarter. The firm had revenue of $384.55 million during the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. As a group, equities analysts expect that Alkermes plc will post -0.69 EPS for the current year.

Analyst Ratings Changes

ALKS has been the subject of a number of recent analyst reports. Bank of America increased their price objective on shares of Alkermes from $34.00 to $36.00 and gave the stock a "neutral" rating in a research note on Thursday, April 9th. HC Wainwright restated a "neutral" rating and set a $43.00 target price on shares of Alkermes in a research note on Thursday, February 26th. Needham & Company LLC upped their target price on shares of Alkermes from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Wednesday. Wall Street Zen lowered Alkermes from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Finally, Wolfe Research initiated coverage on Alkermes in a report on Monday, February 23rd. They set an "outperform" rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.71.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $33.40, for a total value of $300,600.00. Following the sale, the executive vice president directly owned 81,389 shares of the company's stock, valued at approximately $2,718,392.60. The trade was a 9.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the business's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $33.20, for a total value of $67,528.80. Following the completion of the sale, the executive vice president owned 231,558 shares in the company, valued at $7,687,725.60. This represents a 0.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,102 shares of company stock worth $1,265,090 in the last 90 days. 4.59% of the stock is currently owned by corporate insiders.

More Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Q1 results beat expectations — Alkermes reported ($0.43) EPS vs. the consensus loss of ($0.57) and revenue of $392.9M vs. $363.3M expected; revenue was up ~28% year‑over‑year, supporting the stock move higher. Alkermes Q1 Earnings Release
• Positive Sentiment: Management highlighted LUMRYZ momentum on the earnings call as a key driver of commercial growth and reiterated product-level traction that underpins near‑term revenue strength. Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
• Neutral Sentiment: The full earnings‑call transcript is available for investors who want line‑by‑line detail on guidance, cost drivers and commercial commentary. Useful for modeling assumptions and Q&A takeaways. Alkermes Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/metric notes: Zacks and others highlight the beats on revenue and EPS and provide comparisons vs. estimates and year‑ago metrics — helpful context but largely reiterates reported results. ALKS Q1: Key Metrics vs Estimates (Zacks)
• Neutral Sentiment: Insider activity: an EVP sold ~2,034 shares under a pre‑arranged 10b5‑1 plan; small percentage impact and not an unusual liquidity event but worth noting. Insider Sale: David Joseph Gaffin
• Negative Sentiment: FY‑2026 guidance disappointed vs. consensus — Alkermes narrowed EPS guidance to roughly ($0.521)–($0.405), materially below the street's ~($0.09) estimate; revenue guidance was trimmed to ~$1.7–1.8B (vs. consensus near $1.8B). This guidance gap is the main downside risk to the rally and may pressure forward estimates. Alkermes Reports First Quarter 2026 Financial Results

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes' commercial franchise features several approved products.

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.